Otonomy to Host Investor and Analyst Day on October 7, 2016
September 29, 2016 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Sept. 29, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
January 12, 2016 09:27 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 12, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Completes Enrollment in OTIPRIO(TM) Phase 2 Trial and Demonstrates Clinical Feasibility in Patients With Acute Otitis Externa
December 01, 2015 07:00 ET
|
Otonomy, Inc.
SAN DIEGO, Dec. 1, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Initiates Patient Enrollment in U.S. Phase 3 Clinical Trial of OTO-104 in Meniere's Disease
November 18, 2015 07:00 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 18, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Holds Investor and Analyst Day and Provides Corporate Update
October 07, 2015 08:00 ET
|
Otonomy, Inc.
SAN DIEGO, Oct. 7, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Receives FDA Clearance of Investigational New Drug Application for Tinnitus Product Candidate, OTO-311
October 05, 2015 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Oct. 5, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy to Host Investor and Analyst Day on October 7, 2015
September 30, 2015 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Sept. 30, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC) will host an Investor and Analyst Day on Wednesday, October 7, 2015, from 8:30 a.m. to 11:30 a.m. EDT (5:30 a.m. to 8:30 a.m....
Otonomy to Present Results for AuriPro(TM) Phase 3 and OTO-104 Phase 2b Clinical Trials at 2015 AAO-HNSF Annual Meeting
September 24, 2015 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Sept. 24, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Appoints Ted Schroeder to Board of Directors
September 01, 2015 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Sept. 1, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Reports Second Quarter 2015 Financial Results and Provides Corporate Update
August 12, 2015 16:05 ET
|
Otonomy, Inc.
SAN DIEGO, Aug. 12, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...